We are live on ! Find out more
TPC

Takeda Pharmaceutical Company Portfolio holdings

AUM $16.4M
1-Year Est. Return 195.92%
This Fund
S&P 500
This Quarter Est. Return
+25.17%
1 Year Est. Return
+195.92%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$19.6M
AUM Growth
+$3.36M
Cap. Flow
-$9
Cap. Flow %
-0%
Top 10 Hldgs %
99.9%
Holding
11
New
–
Increased
–
Reduced
1
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
LYEL icon
Lyell Immunopharma
LYEL
+$9

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HLVX
1
DELISTED
HilleVax
HLVX
$13.4M 68.43%
6,724,000
– –
OVID icon
2
Ovid Therapeutics
OVID
$485M
$2.49M 12.71%
7,531,996
– –
XLO icon
3
Xilio Therapeutics
XLO
$62.6M
$1M 5.13%
105,366
– –
AMWL icon
4
American Well
AMWL
$217M
$691K 3.53%
77,733
– –
EQ icon
5
Equillium
EQ
$134M
$575K 2.94%
1,824,977
– –
STTK icon
6
Shattuck Labs
STTK
$679M
$408K 2.09%
515,619
– –
LYEL icon
7
Lyell Immunopharma
LYEL
$352M
$364K 1.86%
41,165
-1
-0% -$9
TSBX
8
DELISTED
Turnstone Biologics
TSBX
$322K 1.64%
895,824
– –
THRD
9
DELISTED
Third Harmonic Bio
THRD
$200K 1.02%
36,835
– –
RANI icon
10
Rani Therapeutics
RANI
$88.5M
$104K 0.53%
203,190
– –
LAB icon
11
Standard BioTools
LAB
$306M
$19.8K 0.1%
16,515
– –

Similar funds

KL
KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return
LM
Lasry Marc $15.1M AUM 10.39% 1-Year Est. Return
DADR
Dynamo Administracao de Recursos Rio De Janeiro, Brazil $18.5M AUM 37.41% 1-Year Est. Return
AVM
Avalon Ventures Management La Jolla, California $14.2M AUM 9.35% 1-Year Est. Return
RCMU
Rokos Capital Management (US) New York $14.2M AUM
PM
Pharo Management New York $18.7M AUM
SHM
Sagard Holdings Management Toronto, Ontario, Canada $20M AUM
SI
SQN Investors Menlo Park, California $12.8M AUM

Takeda Pharmaceutical Company's Q2 2025 Portfolio in Review

As of Q2 2025, Takeda Pharmaceutical Company held 11 positions worth $19.6M, up 21% from $16.2M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Trading was light in Q2 2025: portfolio turnover was 0%. Takeda Pharmaceutical Company opened no new positions and made no exits, leaving the 11-position portfolio largely intact.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Takeda Pharmaceutical Company's biggest Q2 2025 reduction was Lyell Immunopharma, cutting an estimated $9.
  • Takeda Pharmaceutical Company's ten largest holdings make up 100% of its $19.6M portfolio in Q2 2025.
  • Takeda Pharmaceutical Company opened 0 new positions and closed 0 in Q2 2025.
  • Takeda Pharmaceutical Company's portfolio value rose 21% quarter-over-quarter to $19.6M.

Based on Takeda Pharmaceutical Company's 13F filing for Q2 2025, filed 8 Aug 2025.